Published in Level 2 journals, first or last author from Oslo University Hospital.
Lindemann K, Berton D, Sehouli J, Christensen RD, Altintas S, Knudsen AØ, Heudel PE, Ataseven B, Vergote I, Lindahl G, Lebreton C, Schochter F, Auranen A, Follana P, Madsen K, Selle F, Petersson KS, Joly F, Braicu EI, Mirza MR(2025) NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer Gynecol Oncol, 199, 79-87(in press) DOI 10.1016/j.ygyno.2025.06.008, PubMed 40592025
Saltnes-Lillegård C, Rustøen T, Beitland S, Puntillo K, Hagen M, Hofsø K(2025) Self-reported symptoms in ICU patients and their impact on long-term outcomes-a prospective multicenter study Intensive Care Med(in press) DOI 10.1007/s00134-025-07995-x, PubMed 40586802
Gunnarsdottir G, Rossholt ME, Nordvik T, Wendel K, Aas MF, Skarbø AB, Aulie VS, Stiris T, Ramm-Pettersen A, Pfeiffer HC, Moltu SJ(2025) High dose arachidonic and docosahexaenoic acid in very preterm infants and neurodevelopment at 2 years - A double-blind randomized controlled trial Clin Nutr, 51, 198-205(in press) DOI 10.1016/j.clnu.2025.05.019, PubMed 40580806
